Literature DB >> 25376263

Incidence of adenoviral DNAemia in Polish adults undergoing allogeneic haematopoietic stem cell transplantation.

Sylwia Rynans1, Tomasz Dzieciątkowski, Maciej Przybylski, Grzegorz W Basak, Patrycja Rusicka, Agnieszka Tomaszewska, Kazimierz Hałaburda, Wiesław W Jędrzejczak, Grażyna Młynarczyk.   

Abstract

Human adenoviruses (HAdV) are important viral pathogens recognized increasingly in immunocompromised hosts, especially in allogeneic haematopoietic stem cell transplant recipients (alloHSCT). The clinical spectrum of HAdV disease ranges from asymptomatic viraemia and mild self-limiting disease to lower respiratory tract infection, multi-organ involvement and even death. Early detection and quantification of HAdV in peripheral blood using real-time PCR (qPCR) assay has been suggested as a useful monitoring tool, but is seldom used for regular surveillance of HAdV in haematology centers. A group of 112 alloHSCT recipients from two hospitals in Warsaw (Poland) was examined in the early post-transplant period using a quantitative qPCR assay. A total of 1,245 serum samples were evaluated for presence of HAdV DNA in patients where 66 (59 %) patients received grafts from unrelated donors whereas the other 46 (41 %) from sibling donors. HAdV sequences were detected in 64 (57 %) of the 112 patients. In 22 of all patients (20 %) HAdV DNA was detected only in a single positive sample, while 42 (37 %) had positive results in two or more subsequent sera. In total, DNAemia was present in 202 sera samples (16 %) with median time to observation of 47 days. Graft-versus-host disease (GvHD) was observed in 18 (28 %) adenovirus-infected transplant recipients and a significant correlation between HAdV infections and GvHD clinical presentation was found (p = 0.018). There is a high prevalence of HAdV infections in HSCT recipients in Poland during early post-transplant period. In consequence, we could only speculate if HAdV DNAemia could be also related to GvHD symptoms, enforcing the important pathogenic role of these viral infections in clinical complications post-alloHSCT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25376263     DOI: 10.1007/s00005-014-0320-z

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  5 in total

1.  Search for Viral Infections in Cerebrospinal Fluid From Patients With Autoimmune Encephalitis.

Authors:  Karol Perlejewski; Agnieszka Pawełczyk; Iwona Bukowska-Ośko; Małgorzata Rydzanicz; Tomasz Dzieciątkowski; Marcin Paciorek; Michał Makowiecki; Kamila Caraballo Cortés; Marta Grochowska; Marek Radkowski; Tomasz Laskus
Journal:  Open Forum Infect Dis       Date:  2020-10-07       Impact factor: 3.835

2.  Viral etiologies in adult patients with encephalitis in Poland: A prospective single center study.

Authors:  Marta Popiel; Karol Perlejewski; Agnieszka Bednarska; Tomasz Dzieciątkowski; Marcin Paciorek; Dariusz Lipowski; Monika Jabłonowska; Hanna Czeszko-Paprocka; Iwona Bukowska-Ośko; Kamila Caraballo Cortes; Agnieszka Pawełczyk; Maria Fic; Andrzej Horban; Marek Radkowski; Tomasz Laskus
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

3.  Pre-Transplant Screening for Latent Adenovirus in Donors and Recipients.

Authors:  Gabriella Piatti
Journal:  Open Microbiol J       Date:  2016-02-02

4.  Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics.

Authors:  Karol Perlejewski; Iwona Bukowska-Ośko; Małgorzata Rydzanicz; Tomasz Dzieciątkowski; Beata Zakrzewska-Pniewska; Aleksandra Podlecka-Piętowska; Agata Filipiak; Krzysztof Barć; Kamila Caraballo Cortés; Agnieszka Pawełczyk; Marek Radkowski; Tomasz Laskus
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

5.  Next-generation sequencing in the diagnosis of viral encephalitis: sensitivity and clinical limitations.

Authors:  Karol Perlejewski; Iwona Bukowska-Ośko; Małgorzata Rydzanicz; Agnieszka Pawełczyk; Kamila Caraballo Cortѐs; Sylwia Osuch; Marcin Paciorek; Tomasz Dzieciątkowski; Marek Radkowski; Tomasz Laskus
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.